Portfolio company
Excellergy Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops trifunctional effector cell response inhibitors to treat patients with severe allergic diseases by removing bound antibodies from immune cells.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Allegria therapeutics
This company develops therapeutic treatments that modulate mast cell activity for patients suffering from allergic and inflammatory diseases.
Solu Therapeutics
This biotechnology company develops antibody-based medicines that target and eliminate disease-driving cells to treat patients with cancer and immunological disorders.
Poplar Therapeutics
The company develops anti-immunoglobulin E antibody therapies to treat patients with food allergies and other atopic conditions.
Tolergyx
This company develops gastrointestinal immunotherapy capsules to treat food allergies in pediatric and adult patients.
Reverb Therapeutics
This biotechnology company develops bispecific antibody therapies that redirect the body's natural cytokines to treat patients with cancer and autoimmune diseases.
Alladapt Immunotherapeutics
This biopharmaceutical company develops oral immunotherapies for patients with single or multiple food allergies to reduce the severity of allergic reactions.
Desentum
This biopharmaceutical company develops allergen immunotherapy products to treat patients suffering from respiratory and food allergies.
Arda Therapeutics
This biotechnology company develops targeted cell depletion therapies to treat chronic diseases by identifying and removing specific pathogenic cells in patients.
